![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/RHEUMA_Dennis-McGonagle-e1598965945791.jpg)
EULAR 2018
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/C1_MCR-EULAR-2018_cover-1-1-225x300.png)
Read the full Report (pdf)
European League Against Rheumatism 13-16 June 2018 Amsterdam, the Netherlands
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/RHEUMA_Dennis-McGonagle-e1598965945791.jpg)
CONTENTS
Online First
Rheumatoid Arthritis
Early, intensive rheumatoid arthritis treatment seems to normalise mortality rates
Switching to biosimilar bDMARDs is safe and efficacious
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/Figure_2_Tapering_status-1.png)
No significant differences when tapering TNF blockers versus csDMARDs
Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey
Biologic drug levels and infection risk, and clinical effectiveness of sarilumab
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/Figure_3_Time_to_first-1.png)
Confirmation of long-term safety profile adalimumab across indications
Ankylosing Spondylitis
Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/Figure_4_TNFi_users-1.png)
Synergistic effect NSAIDs plus TNFi in slowing radiographic progression in ankylosing spondylitis patients
Low bone mineral density is common in axial spondyloarthritis; more awareness required
Osteoporosis and Osteoarthritis
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/03/Table_3_Differences_in_parameters-1.png)